Статья

The benefits and challenges of family genetic testing in rare genetic diseases—lessons from Fabry disease

D. Germain, S. Moiseev, F. Suárez-Obando, F. Al Ismaili, H. Al Khawaja, G. Altarescu, F. Barreto, F. Haddoum, F. Hadipour, I. Maksimova, M. Kramis, S. Nampoothiri, K. Nguyen, D. Niu, J. Politei, L. Ro, D. Vu Chi, N. Chen, S. Kutsev,
2021

Background: Family genetic testing of patients newly diagnosed with a rare genetic disease can improve early diagnosis of family members, allowing patients to receive disease-specific therapies when available. Fabry disease, an X-linked lysosomal storage disorder caused by pathogenic variants in GLA, can lead to end-stage renal disease, cardiac arrhythmias, and stroke. Diagnostic delays are common due to the rarity of the disease and non-specificity of early symptoms. Newborn screening and screening of at-risk populations, (e.g., patients with hypertrophic cardiomyopathy or undiagnosed nephropathies) can identify individuals with Fabry disease. Subsequent cascade genotyping of family members may disclose a greater number of affected individuals, often at younger age than they would have been diagnosed otherwise. Methods: We conducted a literature search to identify all published data on family genetic testing for Fabry disease, and discussed these data, experts’ own experiences with family genetic testing, and the barriers to this type of screening that are present in their respective countries. Results: There are potential barriers that make implementation of family genetic testing challenging in some countries. These include associated costs and low awareness of its importance, and cultural and societal issues. Regionally, there are barriers associated with population educational levels, national geography and infrastructures, and a lack of medical geneticists. Conclusion: In this review, the worldwide experience of an international group of experts of Fabry disease highlights the issues faced in the family genetic testing of patients affected with rare genetic diseases.

Цитирование

Похожие публикации

Источник

Версии

  • 1. Version of Record от 2021-01-01

Метаданные

Об авторах
  • D. Germain
    Universite de Versailles Saint-Quentin-en-Yvelines, Charles University, University of Puthisastra, Universite Paris-Saclay
  • S. Moiseev
    Sechenov First Moscow State Medical University
  • F. Suárez-Obando
    Pontificia Universidad Javeriana
  • F. Al Ismaili
    Royal Hospital
  • H. Al Khawaja
    MCH Hospital
  • G. Altarescu
    Shaare Zedek Medical Center
  • F. Barreto
    Universidade Federal do Parana
  • F. Haddoum
    Centre Hospitalo-universitaire de Mustapha Bacha
  • F. Hadipour
    Atieh Hospital, Tehran
  • I. Maksimova
    Sanofi Russia
  • M. Kramis
    Spanish Hospital, Mexico City
  • S. Nampoothiri
    Amrita Institute of Medical Sciences India
  • K. Nguyen
    Vietnam National Children's Hospital
  • D. Niu
    National Yang-Ming University Taiwan, Veterans General Hospital-Taipei
  • J. Politei
    Neurology Department
  • L. Ro
    Chang Gung Memorial Hospital
  • D. Vu Chi
    Vietnam National Children's Hospital
  • N. Chen
    Shanghai Jiao Tong University School of Medicine
  • S. Kutsev
    Research Centre for Medical Genetics
Название журнала
  • Molecular Genetics and Genomic Medicine
Финансирующая организация
  • Sanofi Genzyme
Номер гранта
  • undefined
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC BY
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus